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Minimally invasive image-guided thermal ablation is becoming increasingly common as an 
alternative to surgery for the treatment of benign thyroid nodules. Among the various techniques 
for thermal ablation, laser ablation (LA) is the least invasive, using the smallest applicators 
available on the market and enabling extremely precise energy deposition. However, in some 
cases, multiple laser fibers must be used simultaneously for the treatment of large nodules. 
In this review, the LA technique is described, and its main clinical applications and results are 
discussed and illustrated.
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Introduction
Thyroid nodules are a very common occurrence in the general population, with a prevalence ranging 
between 20% and 76% [1]. The vast majority of thyroid nodules are benign and incidentally 
detected. Thyroid cancer is relatively uncommon, accounting for approximately 1%-5% of all cancers 
in females and fewer than 2% in males [2]. Benign thyroid nodules generally do not require any 
treatment, unless discomfort, dyspnoea, and hoarseness are present, when nodules present cosmetic 
concerns [3,4], or in cases of hyperfunctioning nodules [5]. The standard treatment of benign thyroid 
nodules still remains surgical resection [4,6]; however, this is a major surgical procedure, requiring 
general anaesthesia and hospitalization, with the complication rate ranging from 2.5% to 8.1% 
[7]. Further, skin scarring around the neck may be an undesired result of this type of surgery. In 
these cases, image-guided thermal ablation (IGTA) has been successfully used to achieve volumetric 
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nodule reduction and symptom improvement [8-11]. IGTA is 
minimally invasive and has been reported to have good clinical 
results, thus indicating its potential to replace surgery as the first-
choice treatment for benign thyroid nodules [12]. Moreover, IGTA 
techniques have been used in limited series for the treatment of 
malignant thyroid cancers, and in cases of recurrence after surgical 
excision of a primary cancer [13-19]. In this setting, IGTA still plays 
a limited role, but it represents a fascinating additional treatment 
within a multidisciplinary approach to thyroid cancer. Recently, new 
guidelines have been released by the Korean Society of Thyroid 
Radiology, including suggestions on indications for radiofrequency 
ablation (RFA) for benign and recurrent cancers [20]. This paper 
includes the most recent and authoritative indications and guidelines 
on the topic of IGTA in thyroid disease, which can also be applied to 
other modalities than RFA. Notably, as several other IGTA techniques 
have been applied in the treatment of thyroid diseases [11], and 
different specialists (radiologists, surgeons, endocrinologists) are 
currently performing IGTA, a more homogeneous standardization of 
indications, techniques, and even reporting criteria would be useful 
[21].
Percutaneous laser ablation (LA) was one of the first techniques 
used to perform IGTA, and is currently used in several different 
clinical scenarios, where its low invasiveness and high precision 
might offer clinical advantages over other ablative techniques [22-
25]. LA was also one of the first techniques used for thyroid thermal 
ablation, and its use has been reported in the treatment of benign, 
hyperfunctioning, and malignant thyroid diseases [24,26-30]. In 
this paper, we review the application of LA in the thyroid, discussing 
its main clinical applications, results, and limitations.
LA Technique
The term "laser" originated as an acronym for "light amplification 
by stimulated emission of radiation." Laser light is highly coherent, 
collimated, and monochromatic, and can be precisely focused to 
deliver a high amount of energy to a very small area [31]. Laser light 
can be vehiculated from the source to a different point through an 
optical fibre, which can be designed according to the desired final 
energy delivery in terms of material, length, and tip shape [32,33]. 
When interacting with biological tissues, laser light undergoes 
scattering and is absorbed by tissues, with consequent deposition of 
energy and a controlled local increase in temperature [34].
Different laser sources (such as diodes or neodymium-yttrium 
aluminium garnet) and wavelengths can be used for clinical 
applications. For human therapies, the 1,064 nm wavelength seem 
to be ideal because of its properties in terms of tissue penetration 
and absorption. Thermal increases in temperature can cause tissue 
destruction by means of various mechanisms, including tissue 
carbonization and coagulative necrosis [35,36]. Irreversible cellular 
damage requires temperature exposure for a certain amount of 
time; it generally begins at a temperature of 46°C when cells are 
exposed for about 60 minutes. At temperatures between 60°C and 
100°C, fast and permanent protein coagulation takes place, while 
temperatures over 105°C-110°C induce tissue carbonization and 
vaporization [36-38]. 
Procedure
For the treatment of benign thyroid nodules with LA, the patient 
is placed on the operating table in the supine position with a 
hyperextended neck, peripheral venous access is obtained, and vital 
parameters are monitored.  
Before treatment, the size, shape, and vascularization of the 
thyroid nodule are assessed using ultrasound. This preliminary 
evaluation needs to plan the number of fibers to use, the preferred 
access route, and the number of illuminations needed, according 
to nodule volume. A needle path as parallel as possible to the 
longest axis of the nodule is preferred. The procedure is performed 
using commercial ultrasound systems and a high-frequency linear 
transducer. A needle-guided attachment with adjustable angle 
selection can be used to help the operator with needle insertion 
to achieve a homogeneous distribution of up to five fibers in the 
nodule. The procedure is generally performed with local anaesthesia 
(2-5 mg of 2% lidocaine) and/or under conscious sedation, even 
though some authors prefer not to use any kind of anaesthesia, in 
order to better monitor the procedure during ablation [39]. Once the 
procedure has been planned, one or more 21-G introducer needles 
are placed in the deeper portion of the target nodule under real-
time ultrasound guidance. If multiple insertions are performed, a 
distance of approximately 1 cm is maintained between the fibers 
[40,41]. Then, a plane-cut quartz optical fiber is inserted and 
advanced up to the introducer needle tip. The introducer needle 
is then partially retracted to expose the fiber tip by at least 5 mm. 
A safety distance of about 10-15 mm should be left between the 
fiber tip and any critical structures to avoid potential complications. 
The first illumination is generally directed into the deepest part of 
the nodule, with a fixed power protocol of 3 W, and a total energy 
delivered for each fiber/illumination between 1,200 and 1,800 J. 
During treatment, gas formation is continuously monitored in real 
time with ultrasound. Laser fibers are subsequently retracted one or 
more times to cover the entire volume of the nodule. This technique 
is also known as the "pull-back technique," and has the advantage 
of reducing the number of direct punctures of the nodule, the 
invasiveness of the procedure, and patients' discomfort.
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After ablation is completed, contrast-enhanced ultrasonography 
(CEUS) can be performed in order to precisely assess the ablated 
volume, and in case of residual vital tissue, ablation can be 
completed under CEUS guidance [42-44]. Patients are generally 
kept under observation for a couple of hours after the procedure 
and then discharged from the hospital. Two cases of benign thyroid 
nodule treatment with LA are shown in Figs. 1 and 2. 
Unlike benign nodules, the purpose of treating malignant nodules 
is to ablate the whole nodule volume, including safe margins of 
at least 3-5 mm. This implies the need for additional care in the 
Fig. 1. Ultrasonography showing laser treatment of a 62-year-old patient with a benign thyroid nodule.
A. Ultrasonography scan before treatment demonstrates a large, isoechoic, non-homogeneous thyroid nodule. B. Contrast-enhanced 
ultrasonography of the same nodule before treatment shows intense enhancement of the nodule. C. Ultrasonography during treatment 
shows the insertion of two laser fibers with the use of dedicated planning software. Hyperechoic areas due to gas formation are seen around 
the needle tips (green and yellow lines, yellow markers, and blue circle line indicate expected fiber path, expected position of needle tip, and 
expected area of ablation with 1 pull-back, respectively). D. Contrast-enhanced ultrasonography performed after treatment demonstrates 
lack of enhancement in the treated area (markers).
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[16]. However, in this setting, the use of CEUS is of paramount 
importance, as it allows the detection of areas of the nodule that 
still need to be treated [45,46]. 
In cases of recurrent thyroid tumours or lymph node metastases, 
identification and preservation of the surrounding vital structures. 
Ideally, malignant nodules should be at least 5 mm distant from the 
thyroid capsule for LA to be suitable. Ablation is then performed 
with the same protocol described above to treat benign nodules 
Fig. 2. Ultrasonography of a 62-year-old patient with a benign thyroid nodule treated with laser ablation.
A. Ultrasonography shows a large, isoechoic, non-homogeneous, predominantly solid thyroid nodule (arrowheads). B. Ultrasonography 
during treatment shows two parallel laser fibers that are clearly visible as hyperechoic lines (arrows), and hyperechoic areas due to gas 
formation during ablation around the tip of the laser fibers. C. Ultrasonography after one pull-back of the two laser (arrows) fibers shows 
the two laser fibers visible as hyperechoic lines, while an area of non-homogeneous hyperechogenicity is seen in the previously ablated area, 
corresponding to residual gas after treatment. D. Ultrasonography taken 2 months after treatment demonstrates a 58% volumetric reduction 
of the treated nodules, which appear as isoechoic and non-homogeneous (arrowheads). 
A B
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target lesions can be adjacent to critical structures. In such cases, a 
variable amount of fluid solution ("hydrodissection") can be injected 
between the lesion and the structure to preserve to increase their 
distance [47-49]. Then, ablation can be performed with a 3 W fixed 
protocol and 1,200-1,800 J, with one or multiple fibers. Ultrasound 
monitoring and CEUS are crucial for the safety and success of this 
procedure, while fusion imaging might help increase visibility for 
deeper lesions [24,46,50,51]. A case of a recurrent thyroid cancer 
treated with LA is shown in Fig. 3. 
Fig. 3. 18-Fludeoxyglucose positron emission tomography (18FDG-PET) and ultrasonography in a 73-year-old patient with previous 
papillary thyroid carcinoma and a cytologically proven metastatic lymph node treated with laser ablation.
A. 18FDG-PET scan shows a left cervical area of focal intense uptake (arrows) representing a metastatic lymph node. B. Ultrasonography 
performed at the same level shows a hypoechoic oval-shaped lymph node, with loss of normal nodal appearance (arrow; c, carotid artery). 
C. Contrast-enhanced ultrasonography demonstrates intense enhancement of the lymph node (asterisk). D. Ultrasonography during the 
treatment shows two laser fibers, visible as hyperechoic lines (arrows), extending into the lymph node. 
A B
C D
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Results of LA in the Thyroid
Benign Nodules
Several papers on initial experiences demonstrated the efficacy 
of LA for inducing volume shrinkage of benign thyroid nodules 
over time. In 2007, a prospective randomized controlled trial by 
Papini et al. [52] analyzed 1-year changes in nodule volume and 
the modification of local symptoms in patients with benign solid 
thyroid nodules randomly assigned to LA, levothyroxine therapy, or 
observation. The authors found significant nodule volume reduction 
(change in volume, -5.2±3.1 mL vs. -0.6±2.2 mL vs. 0.7±2.2 mL, 
respectively), with good treatment toleration by patients and better 
improvement of local symptoms in the LA group than in controls 
(81% vs. 13.3% vs. 0%) [52]. A retrospective study by Achille et al. 
[43] reported a mean nodule volume reduction from 24.2±19.4 mL 
to 6.2±6.6 mL at 6 months (P<0.001) and to 4.5±5.2 mL at 12 
months (P<0.001), with an overall mean nodule volume reduction 
at the end of the study of 84%±13%. Complete resolution of 
cosmetic concerns was found in 87% of participants, and pressure 
symptoms were resolved in 88% [43].
The volume reduction achieved with LA has been shown to 
be stable over time, with protracted clinical benefits even after 
Fig. 3. E. Ultrasonography during ablation shows two hyperechoic 
areas around the tip of the two laser fibers (arrows), reflecting gas 
formation during ablation. F. Post-treatment contrast-enhanced 
ultrasonography demonstrates the lack of enhancement in the 
treated lymph node (asterisk). G. 18FDG-PET after treatment shows 
no uptake at the level of the previously treated lymph node (arrows). 
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a single treatment. A prospective multicentre randomized trial 
investigating the long-term results of LA of benign thyroid nodules 
reported volume reduction in comparison with the baseline volume 
of 49%±22%, 59%±22%, 60%±24%, and 57%±25% at 6, 12, 
24, and 36 months, respectively (P<0.001). The 36-month follow-
up documented a ≥50% reduction in 67.3% of the treated nodules 
(P<0.001). At that time, local pressure symptoms were present in 8% 
of patients, compared to 38% at baseline [30]. Approximately 5% 
of the nodules treated with LA presented partial regrowth over time. 
A retrospective study by Dossing et al. [53] analyzed 78 patients 
with a benign solitary solid nodule treated by LA and observed 
them for a mean follow-up of 36 months (range, 12 to 96 months). 
The overall median nodule volume decreased from 8.2 mL (range, 
2.0 to 25.9 mL) to 3.5 mL (range, 0.6 to 17.6 mL) after 12 months 
(P<0.001) and to 4.1 mL (range, 0.6 to 33.0 mL; P=0.001) at the 
final evaluation. At that time, the median reduction was 51% (range, 
-194% to 95%). Almost all patients included in the study had 
pressure symptoms, which disappeared in 84% of cases. Cosmetic 
concerns disappeared in 72% of patients. Both the self-reported 
pressure symptoms (r=0.4, P=0.02) and the cosmetic complaints 
(r=0.3, P=0.02) were significantly correlated with nodule volume 
reduction after LA [53]. In a prospective, single-centre study, Oddo 
et al. [54] investigated changes in quality of life after LA treatment 
of benign thyroid nodules. The authors reported a significant 
improvement of visual analogue scale scores in all patients after 1 
week, and a significant improvement in goitre symptoms and in the 
general score after 1 and 6 months, as evaluated by the Thyroid-
specific Patient Reported Outcome questionnaire.
One of the main issues of IGTA in benign thyroid nodules is the 
possible regrowth of the treated nodule over time [20]. With LA 
as well, regrowth of the marginal unablated nodule tissue may 
occur, and particularly in case of initially large nodules, subsequent 
treatment can be necessary [55]. As a general rule, retreatment is 
indicated in cases of incomplete symptom relief, volumetric reduction 
<50%, and nodule re-growth [20]. Compared with other ablation 
techniques, such as RFA, LA seems to provide similar results, with 
a possible trend for a lower complication rate and less discomfort. 
In 2015, a systematic review including traditional pooling and a 
Bayesian network meta-analysis of the comparative efficacy of RFA 
and LA was published, reporting apparent superiority of RFA in 
reducing benign thyroid nodule volume [56]. However, that paper 
was based on old results on LA (up to 2007), and mainly on the 
experiences of a single centre (5 out of 7 papers in the LA group 
were from the same centre). Subsequently, in a single-centre study 
comparing 90 patients treated with percutaneous LA or RFA by the 
same group of operators, no difference in the time course of the 
relative volume reduction between the two techniques was found 
[40]. A recent multicentre study, aimed at comparing the effect of 
LA and RFA through a propensity score matching analysis, evaluated 
data from 601 consecutive patients (449 LA and 152 RFA). In that 
study, the mean nodule volume decreased from 21.5±16.5 mL at 
baseline to 8.7±7.7 mL (P<0.001) and to 8.0±7.2 mL (P<0.001) at 
6 and 12 months, respectively, in patients who underwent LA, and 
from 24.5±17.9 mL at baseline to 11.3±10.7 mL (P<0.001) and to 
9.9±9.5 mL (P<0.001) at 6 and 12 months, respectively, in patients 
who underwent RFA. No significant differences in volume reduction 
at different time points was found between the two groups [57]. 
Therefore, based on the more recent literature, the two techniques 
can be considered equivalent in terms of results for nodule volume 
reduction when performed by experienced operators.
The safety of LA has been investigated in several studies, which 
have found high levels of tolerability and low numbers of major 
complications. A multicentre retrospective analysis of 1,837 
treatments from eight centres found an overall complication 
rate of 0.9%, with no life-threatening complications [55]. Major 
complications occurred in 0.5% of cases (8 patients), and all 
consisted of voice changes due to vocal cord palsy, with complete 
recovery after 3 months. Minor complications were reported in 
0.5% of cases (9 patients), including subcapsular or perithyroidal 
hematoma and skin burn. Pain was the most frequent side effect of 
LA and was recorded as mild or moderate, respectively, in 10.6% 
and 1.6% of patients.  
LA can also be successfully used to treat patients with benign 
hyperfunctioning thyroid nodules. In a recent paper, Gambelunghe 
et al. [28] reported 3-year results after LA of 82 patients with 
hyperfunctioning thyroid nodules. They found significant volume 
reduction of the treated nodules from 12 mL (range, 5 to 118 mL) 
to 5 mL (range, 1.2 to 40 mL) after 3 years (P<0.001). Notably, 
better results were achieved in smaller (<15 mL) nodules, where 
the percentage of ablated tissue was higher. Thus, with proper 
patient selection, LA also seems to be a valuable alternative for the 
treatment of hyperfunctioning thyroid nodules [58]. Furthermore, 
a recent pilot study comparing outcomes in patients with large 
toxic nodules treated with LA followed by 131I with those treated 
by 131I alone showed that combined treatment might induce a 
faster resolution of systemic and local symptoms than 131I alone. In 
addition, for three patients, no 131I treatment was needed after LA 
[27]. 
Malignant Thyroid Tumours
Even though surgical excision remains the first therapeutic option 
in patients with thyroid cancer, both for primary disease and for 
recurrence, in recent years LA has been successfully applied to treat 
patients unsuitable for surgery with promising results [17,24,28].
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The incidence of thyroid cancer has increased in the last decades, 
but without a concomitant increase in mortality. This fact might well 
reflect an increase in the early diagnosis of indolent tumours, which 
might have never affected the patient's life. Thus, these tumours, 
which once detected generally require surgical treatment, can be 
regarded as overdiagnosed and overtreated [16,59-62]. In order 
to reduce the adverse events associated with overtreatment, some 
authors have suggested applying an active surveillance strategy to 
small micropapillary thyroid carcinomas [63-65]. In between these 
two strategies, percutaneous thermal ablation has been proposed 
as a possible strategy of care, minimising the invasiveness of the 
treatment, in order to compensate for overdiagnosis and to reduce 
Table 1. Characteristics and results of studies on laser ablation of recurrent thyroid cancers
Study Year
No. of 
patients
No. of treated 
tumours
Tumour dimensions Result
Papini et al. [15] 2013 5 8 Mean: 0.64±0.58 mL Technical success: 100%; no major complications
12-Month follow-up
Mean volume reduction 87.72%±0.11%
Mean serum Tg on LT4 decreased from 8.0±3.2 to 2.0±2.5 ng/mL
Undetectable serum levels of Tg: 3/5 patients (60%)
Mauri et al. [14]a) 2013 15 24  Mean: 1.1±0.4 cm 
(range, 0.6-1.6 cm)
Technical success: 100%; no major complications
6-Month follow-up
Local control: 11/15 patients (73%)
Negative on 18FDG-PET/CT and CEUS: 20/24 nodes (83%)
Normalized serum Tg/TgAb: 6/15 patients (40%)
12-Month follow-up
Local control: 10/14 patients (71.4%)
Negative on 18FDG-PET/CT and CEUS: 16/20 nodes (80%)
Normalized serum Tg/TgAb: 4/10 patients (40%)
Mauri et al. [24] 2016 24 46 Mean: 1.0±0.5 cm 
(range, 0.6-1.6 cm)
Technical success: 100%; no major complications
Mean follow-up of 30±11 months
Tg decreased from 8.40±9.25 to 2.73±4.00 ng/mL
Tg/TgAb normalized: 11/24 patients (45.8%)
Local control: 40/46 lymph nodes (86.9%), no residual disease at 
imaging: 19/24 patients (79.1%)
Estimated mean time to progression: 38.6±2.7 months
Zhou et al. [70] 2016 21 27 Mean volume: 
105.42±114 mm3
Technical success: 100%; no major complications
Completely treated with 1 ablation: 24/27 lymph nodes (88.8%), 
completely treated with 2 ablations: 3/27 (12.2%) 
Significant volumetric reduction to 0.8-2.4 mm3 at the final follow-up 
No regrowth or new lesions at US during follow-up
Zhang et al. [69] 2018 17 21 Mean volume: 
0.110±0.125 mL 
(interquartile range, 
0.01-0.536 mL)
Technical success: 100%; no major complications
Completely ablated in 1 ablation: 18/21 cases (85.7%), completely ablated 
with 2 ablations: 3/21 (14.3%)
Mean follow-up of 17.86±4.704 months (interquartile range, 12-27 
months): no evident recurrence on US
Tg, thyroglobulin; LT4, levothyroxine; 18FDG-PET/CT, 18-Fludeoxyglucose positron emission tomography computed tomography; CEUS, contrast-enhanced ultrasonography; TgAb, 
anti-thryoglobulin antibody; US, ultrasonography. 
a)Preliminary results.
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the negative effects of overtreatment [66,67].
Lee et al. [68], in an ex vivo study, performed LA immediately 
after thyroidectomy in three patients with papillary thyroid cancer. 
Histological analysis of the specimens demonstrated no viable 
tumour cells, and tumour safety margins comparable to those 
obtained through surgery. In 2011, Papini et al. [16] treated an 
incidental papillary thyroid microcarcinoma (PTMC) with LA in a 
patient at high surgical risk. The procedure was well tolerated, 
without complications. Ultrasound-guided fine-needle aspiration 
biopsy and core-needle biopsy performed 12 months after LA 
demonstrated necrotic material and inflammatory cells with no 
viable neoplastic cells [58]. Valcavi et al. [17] treated 3 patients with 
a single PTMC in the operating room under general anaesthesia 
immediately before surgical removal of the thyroid gland. In all 
cases, pathology demonstrated irreversible damage of the ablated 
neoplastic tissue. However, in two cases, papillary microfoci were 
identified in the removed thyroid gland, and in one case a lymph 
node micrometastasis was observed. This highlights one of the main 
issues of IGTA in thyroid malignant tumours, which is related to the 
inability of ultrasonography to detect very small tumour foci within 
the thyroid or in locoregional lymph nodes. Subsequently, Zhang et 
al. [45] published a larger series of 64 cases of PTMC treated with 
LA. Two incomplete ablations were detected by CEUS performed 
immediately after the procedure and a complementary ablation was 
successfully performed. Ultrasound-guided fine-needle aspiration 
at 1, 6, and 12 months after treatment did not show any residual 
tumour. No regrowth of treated lesions could be detected during 
a mean follow-up of 25.7±8.2 months (range, 12 to 42 months). 
A cervical metastatic lymph node was detected on ultrasound and 
cytologically confirmed at 30 months after treatment [45]. Thus, even 
if the present evidence is limited, LA seems to represent a feasible 
and valuable therapeutic option for the treatment of small PTMC.
LA has also been demonstrated to be safe and effective for 
treating recurrent papillary thyroid carcinomas (PTCs) [69] (see Table 
1). Zhou et al. [70] published a retrospective study, conducted in 21 
patients with 27 recurrent PTC lesions treated with LA. Recurrent 
PTCs were identified during routine ultrasound follow-up after 
surgery. Twenty-four lesions received one ablation each and were 
completely ablated. Three incompletely ablated lesions detected 
on CEUS received a subsequent successful ablation. The mean 
follow-up was 14.9±5.9 months (range, 6 to 24 months) [70]. In 
metachronous cervical nodal metastases from PTC, LA may reduce 
or delay highly invasive repeat neck dissections, especially in high-
risk patients. In 2013, Papini et al. [15] reported on the treatment 
with LA of five patients with previous total thyroidectomy and neck 
dissection, with eight new lymph node metastases with a volume 
less than 5 mL and no radioiodine uptake at a post-therapeutic 
131I whole-body scan. A single LA was carried out without major 
complications. Treatment induced the progressive shrinkage of 
metastatic lymph nodes in all patients and no regrowth of the 
successfully treated lesions was detected. Colour Doppler and 
CEUS studies demonstrated an absence of vascularization. Mauri 
et al. [24] used LA to treat 24 patients with elevated serum levels 
of thyroglobulin or anti-thyroglobulin antibodies and a total of 
46 metachronous nodal metastases. All patients had previously 
undergone surgery and radioiodine ablation, were at high surgical 
risk, and had a negative radioiodine scan. The authors obtained 
technical success in all 46 lymph nodes (100%) with no major 
complications. Thyroglobulin levels decreased from 8.40±9.25 ng/mL 
before treatment to 2.73±4.0 ng/mL after treatment (P=0.011), 
with serological conversion in 11 of 24 patients (45.8%). Local 
control was obtained in 40 of the 46 lymph nodes (86.9%) over a 
follow-up of 30±11 months, and no residual disease was identified 
on imaging in 19 of 24 patients (79.1%). Local control was achieved 
in 40 of the 46 lymph nodes (86.9%) at 1 year and in all of the 25 
nodes (100%) that were followed for 3 years, with an estimated 
mean time to progression of 38.6±2.7 months. 
Conclusion
In conclusion, LA is a feasible, safe, and effective technique for 
the treatment of benign thyroid disease. LA may lead to resolution 
of clinical symptoms in the vast majority of cases, with reduced 
invasiveness, a low complication rate, and maintenance of gland 
function. Thus, this treatment can be considered as an effective 
alternative to surgery in patients with benign thyroid nodules. 
Additionally, it may be possible to use LA safely in the treatment of 
malignant thyroid cancer, both primary and metastatic. However, 
the evidence of efficacy of LA in malignant disease is still limited, 
and at present, this technique can only be considered after careful 
multidisciplinary evaluation in cases not suitable for standard 
therapies. 
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